Ray Kopp-Manneh

Valledupar, CES, Colombia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Real-world incidence of G3-G4 adverse events in patients with advanced renal cell carcinoma receiving immune-combinations (ARON-1).

Journal: Frontiers in immunology

Published: February 05, 2026

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Journal: JCO global oncology

Published: October 29, 2025

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study.

Journal: Frontiers in oncology

Published: April 03, 2025

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 23, 2025

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 23, 2025

Genomic Landscape in Prostate Cancer in a Latin American Population.

Genomic Landscape in Prostate Cancer in a Latin American Population.

Journal: JCO global oncology

Published: September 30, 2024

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Journal: The New England journal of medicine

Published: August 21, 2024

Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma.

Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma.

Journal: JCO global oncology

Published: January 25, 2024

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?

Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?

Journal: Cancers

Published: November 07, 2022

Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging.

Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging.

Journal: Cancers

Published: March 24, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026